BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 32725379)

  • 1. Consolidation Therapy in Primary Central Nervous System Lymphoma.
    Kim P; Omuro A
    Curr Treat Options Oncol; 2020 Jul; 21(9):74. PubMed ID: 32725379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
    Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; La Rosée P; Binder M; Fabbri A; Torri V; Minacapelli E; Falautano M; Ilariucci F; Ambrosetti A; Roth A; Hemmaway C; Johnson P; Linton KM; Pukrop T; Sønderskov Gørløv J; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Levis A; Krause SW; Schmoll HJ; Hertenstein B; Rummel M; Smith J; Pfreundschuh M; Cabras G; Angrilli F; Ponzoni M; Deckert M; Politi LS; Finke J; Reni M; Cavalli F; Zucca E; Illerhaus G;
    Lancet Haematol; 2017 Nov; 4(11):e510-e523. PubMed ID: 29054815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
    Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; Krause SW; Levis A; Schmoll HJ; Cavalli F; Finke J; Reni M; Zucca E; Illerhaus G;
    Lancet Haematol; 2016 May; 3(5):e217-27. PubMed ID: 27132696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Options for Recurrent Primary CNS Lymphoma.
    Kaulen LD; Baehring JM
    Curr Treat Options Oncol; 2022 Nov; 23(11):1548-1565. PubMed ID: 36205806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
    Omuro A; Correa DD; DeAngelis LM; Moskowitz CH; Matasar MJ; Kaley TJ; Gavrilovic IT; Nolan C; Pentsova E; Grommes CC; Panageas KS; Baser RE; Faivre G; Abrey LE; Sauter CS
    Blood; 2015 Feb; 125(9):1403-10. PubMed ID: 25568347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.
    Morris PG; Correa DD; Yahalom J; Raizer JJ; Schiff D; Grant B; Grimm S; Lai RK; Reiner AS; Panageas K; Karimi S; Curry R; Shah G; Abrey LE; DeAngelis LM; Omuro A
    J Clin Oncol; 2013 Nov; 31(31):3971-9. PubMed ID: 24101038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
    DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
    Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.
    Hyung J; Hong JY; Yoon DH; Kim S; Park JS; Park CS; Lee SW; Kim JH; Ryu JS; Huh J; Suh C
    Ann Hematol; 2019 Jul; 98(7):1657-1664. PubMed ID: 30989325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
    de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J
    Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
    Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
    J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation.
    Correa DD; Braun E; Kryza-Lacombe M; Ho KW; Reiner AS; Panageas KS; Yahalom J; Sauter CS; Abrey LE; DeAngelis LM; Omuro A
    J Neurooncol; 2019 Sep; 144(3):553-562. PubMed ID: 31377920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine.
    Hattori K; Sakata-Yanagimoto M; Okoshi Y; Kato T; Kurita N; Yokoyama Y; Obara N; Takano S; Ishikawa E; Yamamoto T; Matsumura A; Hasegawa Y; Chiba S
    J Clin Exp Hematop; 2017 Oct; 57(2):41-46. PubMed ID: 28781291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature.
    Dholaria BR; Kumar A; Azzuqua AG; Nishihori T; Kharfan-Dabaja MA; Tun HW; Ayala E
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e273-e280. PubMed ID: 30914301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
    Cheng T; Forsyth P; Chaudhry A; Morris D; Glück S; Russell JA; Stewart DA
    Bone Marrow Transplant; 2003 Apr; 31(8):679-85. PubMed ID: 12692608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.
    Scordo M; Bhatt V; Hsu M; Omuro AM; Matasar MJ; DeAngelis LM; Dahi PB; Moskowitz CH; Giralt SA; Sauter CS
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):38-43. PubMed ID: 27713090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant.
    Oh DH; Chua N; Street L; Stewart DA
    Leuk Lymphoma; 2016; 57(1):28-33. PubMed ID: 25747968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma.
    Steffanoni S; Calimeri T; Anzalone N; Mastaglio S; Bernardi M; Ferreri AJ
    Expert Rev Hematol; 2022 Jan; 15(1):33-43. PubMed ID: 34904506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
    Kasenda B; Ihorst G; Schroers R; Korfel A; Schmidt-Wolf I; Egerer G; von Baumgarten L; Röth A; Bloehdorn J; Möhle R; Binder M; Keller U; Lamprecht M; Pfreundschuh M; Valk E; Fricker H; Schorb E; Fritsch K; Finke J; Illerhaus G
    Leukemia; 2017 Dec; 31(12):2623-2629. PubMed ID: 28559537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study.
    Montemurro M; Kiefer T; Schüler F; Al-Ali HK; Wolf HH; Herbst R; Haas A; Helke K; Theilig A; Lotze C; Hirt C; Niederwieser D; Schwenke M; Krüger WH; Dölken G
    Ann Oncol; 2007 Apr; 18(4):665-71. PubMed ID: 17185743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
    J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.